A Randomized, double-blind, placebo-controlled, single-dose, dose escalation study in healthy participants to evaluate safety, tolerability and pharmacokinetics of intra-vaginal ABI-1968
Phase 1
Completed
- Conditions
- Cervical intraepithelial neoplasia (CIN)Cervical high-grade squamous intraepithelial lesions (HSIL)
- Registration Number
- ACTRN12617000467336
- Lead Sponsor
- Clinical Network Services, Pty Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method